Showing results (81-90 of 831) with videos related to

Sort By:
Pageof 84
Cell Cycle (Georgetown, Tex.)|March 14, 2007
Inhibition of VEGF signaling pathways in multiple myeloma and other malignanciesKlaus Podar, Kenneth C Anderson
British Journal of Haematology|May 20, 2003
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cellsToshiaki Hayashi, Steven P Treon, Teru Hideshima, et al.
British Journal of Haematology|September 15, 2007
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myelomaIris Breitkreutz, Marc S Raab, Sonia Vallet, et al.
Expert Opinion on Investigational Drugs|January 26, 2006
Current therapeutic uses of lenalidomide in multiple myelomaTeru Hideshima, Paul G Richardson, Kenneth C Anderson
Molecular Cancer Therapeutics|November 11, 2011
Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myelomaTeru Hideshima, Paul G Richardson, Kenneth C Anderson
Cancer Control : Journal of the Moffitt Cancer Center|October 29, 2003
Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancersPaul G Richardson, Teru Hideshima, Kenneth C Anderson
Reviews in Clinical and Experimental Hematology|February 7, 2004
Targeting proteasome inhibition in hematologic malignanciesTeru Hideshima, Paul G Richardson, Kenneth C Anderson
Blood|May 16, 2002
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applicationsNicholas Mitsiades, Constantine S Mitsiades, Vassiliki Poulaki, et al.
Pageof 84